TNFRSF10A overexpression + EGFR mutation	Non Small Cell Lung Cancer	TNFRSF10A overexpression + EGFR mutation	Non Small Cell Lung Cancer	erlotinib Resistant: C3 – Early Trials erlotinib Resistant : C3	erlotinib Resistant: C3 – Early Trials erlotinib Resistant : C3
TNFRSF10A overexpression + EGFR mutation	Non Small Cell Lung Cancer	TNFRSF10A overexpression + EGFR mutation	Non Small Cell Lung Cancer	gefitinib Resistant: C3 – Early Trials gefitinib Resistant : C3	gefitinib Resistant: C3 – Early Trials gefitinib Resistant : C3
TNFRSF10A overexpression + EGFR mutation	Non Small Cell Lung Cancer	TNFRSF10A overexpression + EGFR mutation	Non Small Cell Lung Cancer	icotinib Resistant: C3 – Early Trials icotinib Resistant : C3	icotinib Resistant: C3 – Early Trials icotinib Resistant : C3
TNFRSF10A overexpression + EGFR mutation	Non Small Cell Lung Cancer	TNFRSF10A overexpression + EGFR mutation	Non Small Cell Lung Cancer	osimertinib Resistant: D – Preclinical osimertinib Resistant : D	osimertinib Resistant: D – Preclinical osimertinib Resistant : D

TNFRSF10A overexpression + EGFR mutation

Associations